Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Metabolic, pharmacokinetic, and activity profile of the liver stage antimalarial (RC-12)
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
ID
4651547
Author(s)
Dong, Y.; Sonawane, Y.; Maher, S. P.; Zeeman, A. M.; Chaumeau, V.; Vantaux, A.; Cooper, C. A.; Chiu, F. C. K.; Ryan, E.; McLaren, J.; Chen, G.; Wittlin, S.; Witkowski, B.; Nosten, F.; Sriraghavan, K.; Kyle, D. E.; Kocken, C. H. M.; Charman, S. A.; Vennerstrom, J. L.
Metabolic, pharmacokinetic, and activity profile of the liver stage antimalarial (RC-12)
Journal
ACS Omega
Volume
7
Number
14
Pages / Article-Number
12401-12411
Abstract
The catechol derivative RC-12 (WR 27653) (1) is one of the few non-8-aminoquinolines with good activity against hypnozoites in the gold-standard Plasmodium cynomolgi-rhesus monkey (Macaca mulatta) model, but in a small clinical trial, it had no efficacy against Plasmodium vivax hypnozoites. In an attempt to better understand the pharmacokinetic and pharmacodynamic profile of 1 and to identify potential active metabolites, we now describe the phase I metabolism, rat pharmacokinetics, and in vitro liver-stage activity of 1 and its metabolites. Compound 1 had a distinct metabolic profile in human vs monkey liver microsomes, and the data suggested that the O-desmethyl, combined O-desmethyl/N-desethyl, and N,N-didesethyl metabolites (or a combination thereof) could potentially account for the superior liver stage antimalarial efficacy of 1 in rhesus monkeys vs that seen in humans. Indeed, the rate of metabolism was considerably lower in human liver microsomes in comparison to rhesus monkey microsomes, as was the formation of the combined O-desmethyl/N-desethyl metabolite, which was the only metabolite tested that had any activity against liver-stage P. vivax; however, it was not consistently active against liver-stage P. cynomolgi. As 1 and all but one of its identified Phase I metabolites had no in vitro activity against P. vivax or P. cynomolgi liver-stage malaria parasites, we suggest that there may be additional unidentified active metabolites of 1 or that the exposure of 1 achieved in the reported unsuccessful clinical trial of this drug candidate was insufficient to kill the P. vivax hypnozoites.
